

03 FEB 14 AM 11:

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name			
Amgen Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported			
1300 Eye Street, NW; Suite 470 East			
3. Principal Place of Business (if different from line 2)			
City: Washington	State/Zip (or Country) DC	20005	
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
L. Nicole Antorcha	202/354-6112	nickiea@amgen.com	3867-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID #
			31560000

**TYPE OF REPORT** 8. Year  Midyear (January 1-June 30) OR  Year End (July 1-December 31)


9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  Termination Date \_\_\_\_\_

11. No Lobbying Activity

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was:  Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> \$ _____ Income (nearest \$20,000)	<b>EXPENSES</b> relating to lobbying activities for this reporting period were:  Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> \$ <u>1,560,000</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of methods. <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 6033 Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code

Signature  Date 2/14/07

Printed Name and Title Peter B. Teeley, Senior Vice President of Government Relations Page

Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page code, provide information as requested. Attach additional page(s) as needed.**

**15. General issue area code** HCR (one per page)

**16. Specific lobbying issues**

Medicare Prescription Drug Benefit; Medicare Reimbursement

Implementation of sections 1861(s)(2), 1881(b)(11)(B), and 1833(t)(6) of the Social Security Act

Reimportation of Pharmaceuticals

**H.R. 4954:** Medicare Modernization and Prescription Drug Act of 2002

**S. 358:** Medicare Prescription Drug and Modernization Act of 2001

**S. 1135:** Medicare Reform Act of 2001

**S. 2, S. 2729:** Twenty-first Century Medicare Act

**H.R. 1089, S.554:** Access to Innovation for Medicare Patients Act

**S. 2244:** Prescription Drug Price Parity for Americans Act

**S. 812, H. 1862:** Greater Access to Affordable Pharmaceuticals Act

**H.R. 5263, S.2801:** Fiscal Year 2003 Agriculture Appropriations Bill

**S. 2776:** Fiscal Year 2003 Labor, Health and Human Services, and Education Appropriations Bill

**17. House(s) of Congress and Federal agencies contacted**  Check if None

U.S. House of Representatives

U.S. Senate

Department of Health and Human Services


Executive Office of the President

Office of Management and Budget

**18. Name of each individual who acted as a lobbyist in this issue area**

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
Judi A. Teske	
Andrew Swire	
L. Nicole Antorcha	

**19. Interest of each foreign entity in the specific issues listed on line 16 above**  Check if None

Signature  Date 2/14/03

Printed Name and Title Peter B. Teeley, Senior Vice President of Government Relations Page

Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page code, provide information as requested. Attach additional page(s) as needed.**

**15. General issue area code** MMM (one per page)

**16. Specific lobbying issues**

Medicare Prescription Drug Benefit; Medicare Reimbursement

Implementation of sections 1861(s)(2), 1881(b)(11)(B), and 1833(t)(6) of the Social Security Act

AWP Reform

Hospital Outpatient Prospective Payment System (OPPS)

**H.R. 4954:** Medicare Modernization and Prescription Drug Act of 2002

**S. 358:** Medicare Prescription Drug and Modernization Act of 2001

**S. 1135:** Medicare Reform Act of 2001

**S. 2, S. 2729:** Twenty-first Century Medicare Act

**H.R. 1089, S.554:** Access to Innovation for Medicare Patients Act

**17. House(s) of Congress and Federal agencies contacted**  Check if None

- U.S. House of Representatives
- U.S. Senate
- Executive Office of the President
- Centers for Medicare and Medicaid Services
- Department of Health and Human Services
- Office of Management and Budget

**18. Name of each individual who acted as a lobbyist in this issue area**

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
Judi A. Teske	
Andrew Swire	
L. Nicole Antorcha	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature *Peter Teeley* Date 2/14/03

Printed Name and Title Peter B. Teeley, Senior Vice President of Government Relations Page

Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code TAX (one per page)

16. Specific lobbying issues

Corporate Tax Provisions

S. 2119: Reversing the Expatriation of Profits Offshore Act

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
L. Nicole Antorcha	

19. Interest of each foreign entity in the specific issues listed on line 16 above   Check if None

Signature 

Date 2/14/03

Printed Name and Title Peter B. Teeley, Senior Vice President of Government Relations

Page

Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

**16. Specific lobbying issues**

Patent Issues Relevant to Hatch-Waxman Reform

**S. 812, H.R. 1862:** Greater Access to Affordable Pharmaceuticals Act

**17. House(s) of Congress and Federal agencies contacted**  Check if None

U.S. House of Representatives  
U.S. Senate

**18. Name of each individual who acted as a lobbyist in this issue area**

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
L. Nicole Antorcha	

19. Interest of each foreign entity in the specific issues listed on line 16 above   Check if None

Signature 

Date 2/14/03

